A new approach to migraines - A review of rimegepant; its merits, synthesis, and pharmacological characteristics

28 September 2022, Version 1
This content is a preprint and has not undergone peer review at the time of posting.


Migraines in the modern day represent a significant problem, however, the current treatment options come with significant risks. This paper reviews rimegepant, its pharmacological characteristics, and possible synthetic pathways, focusing on ease of synthesis, green chemistry, and scalability. The review reveals a biocatalytic approach to be a promising candidate for industrial scale-up with relatively mild conditions.


stereoselective synthesis
CGRP receptor antagonists


Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.